Phaseline

Targets › GLS1

GLS1 (Glutaminase kidney isoform, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. (UniProt, O94925)

Open in Phaseline: the race on GLS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
M.D. Anderson Cancer CenterIACS-6274
Glutaminase-1 inhibitor
GLS1Phase 1Advanced Endometrial CarcinomaMar 2028

Conditions

Advanced Endometrial Carcinoma (1)

Modalities

mixed (1)

Companies

M.D. Anderson Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.